Introduction: SARS-CoV-2 continues to raise health and socio-economical concerns globally. The recent discovery of the B.1.1.529 (Omicron) variant with its critical mutations has heightened the debate about the need for a better global vaccination rollout to prevent the emergence of new SARS-CoV-2 strains. Optimizing vaccine rollout in Africa is crucial for the management of the pandemic and preventing the rise of new strains. To better direct efforts and interventions it is important to know what parts of the continent necessitate more attention. Material and Methods: 30 African countries were grouped in five geographical subregions, six countries for each subregion. Data on confirmed cases, doses administered, fully vaccinated, and deaths were extracted from the Johns Hopkins Coronavirus Resource Center database. The ANOVA test evaluated differences in means for these variables classified by subregions. The correlation test and the linear regression examined the relationship between these independent variables and total deaths. Results: There was a significant regional difference in confirmed cases (P<0.0001), and in fully vaccinated (P=0.01) across the five subregions. The overall model showed that there is a significant regional difference in the three variables’ effect on total deaths (P<0.0001). The linear regression indicated an association between the total number of deaths in relation to the confirmed cases, doses administered, and fully vaccinated (P<0.0001). Discussion: This study indicates that a relation exists between total deaths and the variables confirmed cases, doses administered, and fully vaccinated. More importantly, African countries grouped in geographical subregions perform differently in terms of vaccine rollout, and that offers insights for better and oriented interventions.
6 August 2020 in Iberoamerican Journal of Medicine
This study aimed to identify the factors influencing the use of electronic pillboxes in Africa and to outline their implications for practice and policy. A
10 July 2026 in Bulletin of the National Research Centre
Background: Maintaining high levels of medication adherence is essential for the success of antiretroviral therapy (ART), yet non-adherence remains a persistent challenge in resource-limited settings. Smart Pillboxes (SPBs) offer a promising digital solution by providing real-time adherence monitoring and clinical decision support. However, the successful implementation of these tools among people living with HIV (PLHIV) depends on understanding user-level barriers. This study examines the sociodemographic, behavioral, and infrastructural factors that influence the willingness to adopt SPBs among people living with HIV in Cameroon. Methods: This cross-sectional study involved 153 PLHIV recruited from clinical sites in the Center Region of Cameroon. The Diffusion of Innovations (DOI) framework informed the conceptual categorization. Due to convergence issues with log-binomial models, statistical analyses utilized multivariable modified Poisson regressions with robust standard errors to identify predictors of adoption intent. Global model significance was assessed via the Wald Chi-square test. A bootstrap procedure was applied to validate the stability of identified predictors. Results: At the outset, 60.8% of participants self-classified as adopters. Females were the majority (53%), and over half of the participants were single (55.6%). The final multivariable model demonstrated high statistical significance (Wald $$\:{\chi\:}^{2}$$ = 29.5, p = 0.0019). Higher educational attainment (MA; aRR = 1.64, p = 0.004) and frequent medication forgetfulness (aRR = 1.35, p = 0.026) were identified as robust facilitators of adoption willingness. Adoption intent was significantly attenuated by the use of phone reminders (aRR = 0.77, p = 0.049) and unemployment (aRR = 0.64, p = 0.049). Conclusion: Adoption intent of SPBs is driven by a synergy of socioeconomic status and felt behavioral needs. While infrastructure is a necessary baseline, educational attainment and perceived utility are the primary determinants of adoption intent in this urban population.
Most studies on the HIV reservoir have focused on resting memory CD4+ T cells. This focus has shaped how researchers think about viral persistence and has guided the development of “shock-and-kill” strategies. But new research shows the reservoir is much broader. It includes myeloid, stromal, and non-immune cells, each with its own ways of maintaining viral latency. Macrophages, microglia, and dendritic cells can carry replication-competent HIV. Different epigenetic mechanisms and transcription factors regulate their proviruses, highlighting the need to determine whether cure strategies designed primarily for T cells can also address these reservoirs. The reservoir is also shaped by its location in the body. The brain, gut, and liver each create different challenges for persistence and treatment, challenges that cannot be explained just by cell type. We argue that the HIV reservoir is not a single entity. Instead, it is a collection of unique latency programs in different cells and tissues. Ignoring this complexity is a major gap in current cure research. To make progress, we need to map the reservoir’s true distribution, use the right assays for each cell type, and design drugs and therapies that match this diversity.